Efficacy and Tolerability of Benzodiazepines versus Antidepressants in Anxiety Disorders: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Background: Placebo-controlled trials showed that both benzodiazepines (BDZ) and antidepressant drugs (AD) are effective in treating anxiety disorders. However, in the last years a progressive shift in the prescribing pattern from BDZ to newer AD has taken place. The aim of this systematic review and meta-analysis is to analyze whether controlled comparisons support such a shift. Methods: CINHAL, the Cochrane Library, MEDLINE, PubMed and Web of Science were searched from inception up to December 2012. A total of 22 studies met the criteria for inclusion. They were mostly concerned with tricyclic antidepressants (TCA; 18/22) and involved different anxiety disorders. In order to reduce clinical heterogeneity, only the 10 investigations that dealt with the comparison between TCA and BDZ in panic disorder were submitted to meta-analysis, whereas the remaining papers were individually summarized and critically examined. Results: According to the systematic review, no consistent evidence emerged supporting the advantage of using TCA over BDZ in treating generalized anxiety disorder (GAD), complex phobias and mixed anxiety-depressive disorders. Indeed, BDZ showed fewer treatment withdrawals and adverse events than AD. In panic disorder with and without agoraphobia our meta-analysis found BDZ treatments more effective in reducing the number of panic attacks than TCA (risk ratio, RR = 1.13; 95% CI = 1.01-1.27). Furthermore, BDZ medications were significantly better tolerated than TCA drugs, causing less discontinuation (RR = 0.40; 95% CI = 0.20-0.57) and side effects (RR = 0.41; 95% CI = 0.34-0.50). As to newer AD, BDZ trials resulted in comparable or greater improvements and fewer adverse events in patients suffering from GAD or panic disorder. Conclusions: The change in the prescribing pattern favoring newer AD over BDZ in the treatment of anxiety disorders has occurred without supporting evidence. Indeed, the role and usefulness of BDZ need to be reappraised.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, benzodiazepines are not indicated for the long-term treatment of anxiety, insomnia, or stress, for which they are most often prescribed [81–83].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [82]
In the citing paper
“Antipsychotics rapidly eliminated or rapidly dissociated from the D2 receptors (i.e., clozapine, quetiapine) [161, 162] are known to have greater risks of rebound when medication is decreased, switched, or discontinued [13, 154, 156, 157, 163].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [162]
In the citing paper
“In a systematic review, benzodiazepines were associated with fewer withdrawals and adverse events than AD in anxiety disorders.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
In the citing paper
“Such change has occurred without any supporting evidence.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
In the citing paper
“In panic disorder, whether accompanied by agoraphobia or not, benzodiazepine treatment was more effective in reducing the number of panic attacks than antidepressant medications.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Davis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE
Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb02357.x · Cited by 1,326
Research works printed but not linked: 1
- 10.1159%2f000334112 · DOI
Cited by
Sex differences in anxiety and depression clinical perspectives
Altemus, M., Sarvaiya, N., & Neill Epperson, C. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.05.004 · Cited by 1,413
“Of all of the anxiety disorders, panic disorder is particularly responsive to benzodiazepine treatment (Offidani et al., 2013).”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Self-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Murphy, S. E., Capitão, L. P., Giles, S. L. C., Cowen, P. J., Stringaris, A., & Harmer, C. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00154-1 · Cited by 112
Bais, B., Molenaar, N. M., Bijma, H. H., Hoogendijk, W. J. G., Mulder, C. L., Luik, A. I., den Berg, M. P. L., & Kamperman, A. M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.014 · Cited by 107
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103
“In a comparison between the withdrawal reactions of patients treated with benzodiazepines and antidepressant medication for panic disorder, Offidani and colleagues found both classes of drugs to be associated with the same type of problem upon discontinuation [Offidani et al. 2013].”
BackgroundVázquez, G. H., Baldessarini, R. J., & Tondo, L. (2014) · Depression and Anxiety · doi:10.1002/da.22248 · Cited by 93
Pharmacological treatment for generalized anxiety disorder in adults: an update
Reinhold, J. A., & Rickels, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1059424 · Cited by 82
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Self-citationAnxiety: An ignored aspect of Parkinson’s disease lacking attention
Khatri, D. K., Choudhary, M., Sood, A., & Singh, S. B. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110776 · Cited by 94
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
“[25] noted that only a few studies compared BDZs with newer antidepressants (paroxetine and venlafaxine), with the findings suggesting no difference in efficacy (or potentially greater efficacy of BDZs) and better tolerability of BDZs.”
BackgroundResultUso racional de benzodiacepinas: hacia una mejor prescripción
Domínguez, V., Collares, M., Ormaechea, G., & Tamosiunas, G. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 88
Mixed Depression: Clinical Features and Predictors of Its Onset Associated with Antidepressant Use
Sani, G., Napoletano, F., Vöhringer, P. A., Sullivan, M., Simonetti, A., Koukopoulos, A., Danese, E., Girardi, P., & Ghaemi, N. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000358808 · Cited by 80
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Self-citationWeisberg, D. F., Gordon, K. S., Barry, D. T., Becker, W. C., Crystal, S., Edelman, E. J., Gaither, J. R., Gordon, A. J., Goulet, J. L., Kerns, R. D., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000591 · Cited by 83
GABAergic implications in anxiety and related disorders
Arora, I., Mal, P., Arora, P., Paul, A., & Kumar, M. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150218 · Cited by 83
Role of Benzodiazepines in Anxiety Disorders
Balon, R., & Starčević, V. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9705-0_20 · Cited by 82
Treatment-resistant panic disorder: clinical significance, concept and management
Chen, M., & Tsai, S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.001 · Cited by 80
Nordahl, H. M., Vogel, P. A., Morken, G., Stiles, T. C., Sandvik, P., & Wells, A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447013 · Cited by 64
Benzodiazepines as a monotherapy in depressive disorders: a systematic review
Benasi, G., Guidi, J., Offidani, E., Balon, R., Rickels, K., & Fava, G. A. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000486696 · Cited by 79
Self-citationEvidence-based medicine was bound to fail: a report to Alvan Feinstein
Fava, G. A. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.01.012 · Cited by 79
Self-citationFiorillo, A., Dell'Osso, B., Albert, U., Atti, A. R., Carmassi, C., Carrà, G., Cosci, F., Del Vecchio, V., Di Nicola, M., Ferrari, S., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s83130 · Cited by 67
Park, T. W., Larochelle, M. R., Saitz, R., Wang, N., Bernson, D., & Walley, A. Y. (2020) · Addiction · doi:10.1111/add.14886 · Cited by 78
“Benzodiazepines are efficacious treatments for anxiety and insomnia(19,20), two of the main reasons why patients with opioid use disorder take them(21,22).”
BackgroundDiscontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Fava, G. A., & Belaise, C. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000492693 · Cited by 77
Self-citationAquatic blues: Modeling depression and antidepressant action in zebrafish
Nguyen, M., Stewart, A., & Kalueff, A. V. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.03.003 · Cited by 77
Analytical Methods Used for the Detection and Quantification of Benzodiazepines
Qriouet, Z., Qmichou, Z., Bouchoutrouch, N., Mahi, H., Cherrah, Y., & Sefrioui, H. (2019) · Journal of Analytical Methods in Chemistry · doi:10.1155/2019/2035492 · Cited by 76
Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland
Taipale, H. T., Särkilä, H., Tanskanen, A. J., Kurko, T., Taiminen, T. J., Tiihonen, J., Sund, R., Tuulio‐Henriksson, A., Saastamoinen, L., & Hietala, J. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19029 · Cited by 76
Yoshinaga, N., Matsuki, S., Niitsu, T., Sato, Y., Tanaka, M., Ibuki, H., Takanashi, R., Ohshiro, K., Ohshima, F., Asano, K., et al. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000444221 · Cited by 60
Scopoletin ameliorates anxiety-like behaviors in complete Freund’s adjuvant-induced mouse model
Luo, L., Sun, T., Yang, L., Liu, A., Liu, Q.-Q., Tian, Q., Wang, Y., Zhao, M., & Yang, Q. (2020) · Molecular Brain · doi:10.1186/s13041-020-0560-2 · Cited by 73
CO2 exposure as translational cross-species experimental model for panic
Leibold, N. K., van den Hove, D., Viechtbauer, W., Buchanan, G. F., Goossens, L., Lange, I., Knuts, I., Lesch, K., Steinbusch, H. W. M., & Schruers, K. R. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.162 · Cited by 72
Jain, B., Jain, R., Nowak, P. M., Ali, N., Ansari, M. N., Kabir, A., Chandravanshi, L. P., & Sharma, S. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117524 · Cited by 70
Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs
Fava, G. A., & Cosci, F. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19com12794 · Cited by 69
Self-citationPsychological therapy for anxiety in bipolar spectrum disorders: A systematic review
Stratford, H. J., Cooper, M. J., Di Simplicio, M., Blackwell, S. E., & Holmes, E. A. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.11.002 · Cited by 63
Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
Cloos, J.-M., Bocquet, V., Rolland-Portal, I., Koch, P., & Chouinard, G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000434755 · Cited by 57
Antidepressants and benzodiazepines for panic disorder in adults
Bighelli, I., Trespidi, C., Castellazzi, M., Cipriani, A., Furukawa, T. A., Girlanda, F., Guaiana, G., Koesters, M., & Barbui, C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011567.pub2 · Cited by 57
The rise and fall and rise of benzodiazepines: a return of the stigmatized and repressed
Balon, R., Starčević, V., Silberman, E. K., Cosci, F., Dubovsky, S. L., Fava, G. A., Nardi, A. E., Rickels, K., Salzman, C., Shader, R. I., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0773 · Cited by 57
Self-citationShinfuku, M., Kishimoto, T., Uchida, H., Suzuki, T., Mimura, M., & Kikuchi, T. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000276 · Cited by 45
Krieger, J.-P., Asker, M., van der Velden, P., Börchers, S., Richard, J. E., Marić, I., Longo, F., Singh, A., de Lartigue, G., & Skibicka, K. P. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.04.020 · Cited by 55
Benzodiazepines or related drugs and risk of pneumonia: A systematic review and meta‐analysis
Sun, G., Zhang, L., Zhang, L., Wu, Z., & Hu, D. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5048 · Cited by 55
Long-term use of benzodiazepines in older patients in Germany: a retrospective analysis
Jacob, L., Rapp, M. A., & Kostev, K. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317696454 · Cited by 41
Diazepam effects on local cortical neural activity during sleep in mice
McKillop, L. E., Fisher, S. P., Milinski, L., Krone, L. B., & Vyazovskiy, V. V. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114515 · Cited by 51
Shafiekhani, M., Mirjalili, M., & Vazin, A. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s176079 · Cited by 48
Quagliato, L. A., Cosci, F., Shader, R. I., Silberman, E. K., Starcevic, V., Balon, R., Dubovsky, S. L., Salzman, C., Krystal, J. H., Weintraub, S. J., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119859372 · Cited by 35
Balon, R. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353599 · Cited by 45
Cosci, F., & Chouinard, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00007-x · Cited by 41
Carmona, F., Coneglian, F. S., Batista, P. A., Aragon, D. C., Angelucci, M. A., Martínez, E. Z., & Pereira, A. M. S. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112060 · Cited by 36
Initiation and long‐term use of benzodiazepines and Z‐drugs in bipolar disorder
Wingård, L., Taipale, H. T., Reutfors, J., Westerlund, A., Bodén, R., Tiihonen, J., Tanskanen, A. J., & Andersen, M. T. (2018) · Bipolar Disorders · doi:10.1111/bdi.12626 · Cited by 35
Benzodiazepines: A Valuable Tool in the Management of Cardiovascular Conditions
Balon, R., Rafanelli, C., & Sonino, N. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000493015 · Cited by 34
Baldaçara, L., Paschoal, A. B., Pinto, A. F., Loureiro, F. F., Antonio, L. A. V. G., Veiga, D. D. L., Almeida, T. M., Santos, D. C. D., Malloy‐Diniz, L. F., Mello, M. F., et al. (2024) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2023-3235 · Cited by 34
Zoroufchi, B. H., Doustmohammadi, H., Mokhtari, T., & Abdollahpour, A. (2020) · Revista Internacional de Andrología · doi:10.1016/j.androl.2019.08.003 · Cited by 31
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C. R., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19203 · Cited by 31
Fava, G. A. (2014) · World Psychiatry · doi:10.1002/wps.20108 · Cited by 31
Self-citationBenzodiazepines in anxiety disorders: Reassessment of usefulness and safety
Rickels, K., & Moeller, H. J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1500031 · Cited by 30
“Offidani et al. (2013) concluded ‘Change in the prescribing pattern favoring newer ADs over BZs in the treatment of anxiety disorders has occurred without supporting evidence.”
BackgroundInfluentialCosci, F., Mansueto, G., Faccini, M., Casari, R., & Lugoboni, F. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.06.008 · Cited by 29
Shah, A., & Northcutt, J. (2018) · Annals of General Psychiatry · doi:10.1186/s12991-018-0190-6 · Cited by 23
Clinical Methodology Matters in Epidemiology: Not All Benzodiazepines Are the Same
Cosci, F., Guidi, J., Balon, R., & Fava, G. A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000437201 · Cited by 27
Self-citationThronson, L. R., & Pagalilauan, G. L. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.001 · Cited by 27
Wang, S., Kim, J.-B., Sakong, J. K., Suh, H.-S., Oh, K., Woo, J., Yoo, S.-W., Lee, S. M., Lee, S.-Y., Lim, S.-W., et al. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.2.177 · Cited by 26
Rickels, K. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353502 · Cited by 25
The hidden costs of financial conflicts of interest in medicine
Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442694 · Cited by 25
Self-citationThe Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Offidani, E., Fava, G. A., & Sonino, N. (2014) · CNS Drugs · doi:10.1007/s40263-014-0184-0 · Cited by 23
“Further, in a recent systematic review, no consistent evidence emerged supporting the advantage of using antidepressant drugs over benzodiazepines in treating anxiety disorders in adults [25].”
BackgroundSelf-citationAntidepressants and benzodiazepines for panic disorder in adults
Guaiana, G., Barbui, C., Bighelli, I., Trespidi, C., Chiodo, D., Cipriani, A., Davies, S., & Koesters, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011567 · Cited by 23
A Cross-Sectional study of Psychiatric disorders in Medical Sciences Students
Jamshidi, F., Mogehi, S., Cheraghi, M., Jafari, S., Kabi, I., & Rashidi, L. (2017) · Materia Socio Medica · doi:10.5455/msm.2017.29.188-191 · Cited by 20
Need for a realistic appraisal of benzodiazepines
Balon, R., Fava, G. A., & Rickels, K. (2015) · World Psychiatry · doi:10.1002/wps.20219 · Cited by 22
Self-citationHeesbeen, E. J., Kampen, T. V., Verdouw, P. M., Lissa, C. J. V., Bijlsma, E. Y., & Groenink, L. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06645-2 · Cited by 21
Discontinuing Benzodiazepines: Best Practices
Guaiana, G., & Barbui, C. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000032 · Cited by 18
Groenink, L., Verdouw, P. M., Bakker, B., & Wever, K. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.062 · Cited by 18
Systematics and treatment of anxiety disorders
Sivolap, Y. P. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2020120071121 · Cited by 17
Benzodiazepine absetzen im Alter: Wann und, wenn ja, wie?
Wolter, D. K. (2017) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-016-1171-5 · Cited by 16
Discontinued anxiolytic drugs (2009 – 2014)
Mandrioli, R., & Mercolini, L. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.998335 · Cited by 14
Bais, B., Munk‐Olsen, T., Bergink, V., & Liu, X. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112993 · Cited by 14
Benzodiazepines in Anxiety Disorders
Fava, G. A., Balon, R., & Rickels, K. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0182 · Cited by 14
Self-citationNardi, A. E., & Quagliato, L. A. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524730 · Cited by 14
Primary care hypnotic and anxiolytic prescription: Reviewing prescribing practice over 8 years
Hughes, L., Raitt, N., Riaz, M., Baldwin, S.-J., Erskine, K., & Graham, G. (2016) · Journal of Family Medicine and Primary Care · doi:10.4103/2249-4863.197312 · Cited by 13
Fava, G. A., Benasi, G., & Cosci, F. (2017) · Verhaltenstherapie · doi:10.1159/000460826 · Cited by 14
Self-citationFiroozabadi, A., Kolouri, S., Zarshenas, M. M., Salehi, A., Mosavat, S. H., & Dastgheib, S. A. (2017) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2017.08.003 · Cited by 13
Debate: Are Benzodiazepines Appropriate Treatments for Patients with Substance Use Disorders? Yes
Park, T. W. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000292 · Cited by 13
Representation of Benzodiazepines in Treatment Guidelines: The Paradox of Undesirable Objectivity
Starčević, V. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524772 · Cited by 12
Research status and trends of physical activity on depression or anxiety: a bibliometric analysis
Zhang, X., Ye, F., Yin, Z., Li, Y., Bao, Q.-N., Xia, M., Chen, Z., Zhong, W., Wu, K., Yao, J., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1337739 · Cited by 11
Learning Mechanisms in Fear and Anxiety: It Is Still Not What You Thought It Was
Scheveneels, S., Boddez, Y., & Hermans, D. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108140416.002 · Cited by 11
Panic Attacks and Panic Disorder
Bonevski, D., & Naumovska, A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.86898 · Cited by 12
Cybersuicide: Online-Assisted Suicide
Moir, C.-L., Tzani, C., Ιωάννου, Μ., Lester, D., Synnott, J., & Williams, T. J. V. (2023) · Journal of Police and Criminal Psychology · doi:10.1007/s11896-023-09602-5 · Cited by 10
White, S. W., Squires, G. D., Smith, S. J., Wright, G. M., Sufka, K. J., Rimoldi, J. M., & Gadepalli, R. S. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173588 · Cited by 10
Schmalbach, I., Witthöft, M., Strauss, B. M., Joraschky, P., & Petrowski, K. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02882-3 · Cited by 9
Suchtpotenzial und andere Risiken von Benzodiazepinen und Z-Drugs im Alter
Wolter, D. K. (2017) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000474 · Cited by 9
Silberman, E. K., Nardi, A. E., Starčević, V., Balon, R., Cosci, F., Fava, G. A., Salzman, C., Shader, R. I., & Sonino, N. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23com14959 · Cited by 9
Self-citationBenefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don’t Know
Silberman, E. K. (2025) · Drugs · doi:10.1007/s40265-025-02261-2 · Cited by 8
Abd‐AlGhafar, W. N., Aboshabana, R., El-Shaheny, R. N., & Tolba, M. M. (2025) · Talanta Open · doi:10.1016/j.talo.2025.100475 · Cited by 8
Kelm, Z., Klapchar, K., Kieliszak, C. R., & Selinsky, C. R. (2018) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2018.066 · Cited by 8
Perfil de riesgo de los antidepresivos inhibidores selectivos de la recaptación de serotonina (ISRS)
Pérez, V., Speranza, N., Tamosiunas, G., & Ormaechea, G. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 8
Carlo, V. D., Grancini, B. M., Vismara, M. E. M., Benatti, B., Arici, C., Cremaschi, L., Cirnigliaro, G., Degoni, L., Oldani, L., Palazzo, C., et al. (2019) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2695 · Cited by 8
Metadata
- Authors
- Offidani, E., Guidi, J., Tomba, E., & Fava, G. A.
- Affiliations
- University of Bologna (IT)
- University at Buffalo, State University of New York (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 82
- Issue
- 6
- Pages
- 355-362
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2058854656
- Semantic Scholar
- 51250bb52dc9a5838fd9cb633760bcbf3bfe6a5e
- Cited by
- 166
- References
- 64
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 17 · 2023: 8 · 2022: 12 · 2021: 6 · 2020: 17 · 2019: 12 · 2018: 16 · 2017: 17 · 2016: 13 · 2015: 16 · 2014: 17 · 2013: 2
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- benzodiazepines, antidepressants, anxiety disorders, tricyclic antidepressants, panic disorder, generalized anxiety disorder, mixed anxiety-depressive disorder, treatment efficacy, tolerability, adverse events, treatment withdrawal, prescribing patterns
- MeSH terms
- Antidepressive Agents, Antidepressive Agents, Tricyclic, Anxiety Disorders, Benzodiazepines, Humans, Obsessive-Compulsive Disorder, Practice Patterns, Physicians', Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.